Welcome to the InfoSci Platform
Cancer Drug Delivery: Pharmacogenetics, Biomarkers, and Targeted Therapies

Cancer Drug Delivery: Pharmacogenetics, Biomarkers, and Targeted Therapies

Jai N. Patel, Jeryl Villadolid
Copyright: © 2017 |Pages: 44
ISBN13: 9781522507543|ISBN10: 152250754X|EISBN13: 9781522507550
DOI: 10.4018/978-1-5225-0754-3.ch003
Cite Chapter Cite Chapter

MLA

Patel, Jai N., and Jeryl Villadolid. "Cancer Drug Delivery: Pharmacogenetics, Biomarkers, and Targeted Therapies." Recent Advances in Drug Delivery Technology, edited by Raj K. Keservani, et al., IGI Global, 2017, pp. 52-95. https://doi.org/10.4018/978-1-5225-0754-3.ch003

APA

Patel, J. N. & Villadolid, J. (2017). Cancer Drug Delivery: Pharmacogenetics, Biomarkers, and Targeted Therapies. In R. Keservani, A. Sharma, & R. Kesharwani (Eds.), Recent Advances in Drug Delivery Technology (pp. 52-95). IGI Global. https://doi.org/10.4018/978-1-5225-0754-3.ch003

Chicago

Patel, Jai N., and Jeryl Villadolid. "Cancer Drug Delivery: Pharmacogenetics, Biomarkers, and Targeted Therapies." In Recent Advances in Drug Delivery Technology, edited by Raj K. Keservani, Anil K. Sharma, and Rajesh Kumar Kesharwani, 52-95. Hershey, PA: IGI Global, 2017. https://doi.org/10.4018/978-1-5225-0754-3.ch003

Export Reference

Mendeley
Favorite

Abstract

Advancements in cancer drug delivery have led to the development of personalized oncology care through molecularly-driven targeted therapies. Understanding molecular and cellular mechanisms which drive tumor progression and resistance is critical in managing new treatment strategies which have shifted from empiric to biomarker-directed therapy selection. Biomarker-directed therapies have improved clinical outcomes in multiple malignancies as monotherapy and in combination with other treatment modalities, however the changing scope of treatment options presents new opportunities and challenges for research. Furthermore, pharmacogenetics may provide a rationale method of personalizing anticancer drug dosing and supportive care management for oncology patients. This chapter reviews biomarker classifications and pharmacogenetics in anticancer therapy and supportive care. Examples of biomarker-directed therapies and clinical assays, in addition to future directions of molecular profiling in oncology therapy management are discussed.

Request Access

You do not own this content. Please login to recommend this title to your institution's librarian or purchase it from the IGI Global bookstore.